SSA
CARM

Schonfeld Strategic Advisors’s Carisma Therapeutics CARM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-630
Closed -$10K – 2171
2021
Q3 		$10K Sell
630
-190,780
-100% -$9.16M ﹤0.01% 2083
2021
Q2 		$17.7M Buy
191,410
+23,705
+14% +$1.51M 0.19% 152
2021
Q1 		$8.72M Buy
167,705
+150,246
+861% +$7.09M 0.11% 261
2020
Q4 		$471K Sell
17,459
-2,931
-14% -$74.3K 0.01% 1052
2020
Q3 		$571K Buy
+20,390
New +$408K 0.01% 875
2019
Q3 		– Sell
-62,785
Closed -$1.88M – 1032
2019
Q2 		$1.88M Buy
+62,785
New +$1.88M 0.07% 303
2019
Q1 		– Sell
-47,518
Closed -$1.35M – 1058
2018
Q4 		$1.35M Buy
47,518
+8,613
+22% +$275K 0.05% 403
2018
Q3 		$1.67M Buy
+38,905
New +$1.52M 0.07% 323

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Schonfeld Strategic Advisors's CARM Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 630 shares — an estimated $10K sold.

Schonfeld Strategic Advisors first reported a position in CARM in Q3 2018 and held it in 8 quarters. The position peaked at $17.7M in Q2 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 630 Carisma Therapeutics shares in Q4 2021, an estimated $10K.
  • Schonfeld Strategic Advisors first reported a position in Carisma Therapeutics in Q3 2018 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Carisma Therapeutics position peaked at $17.7M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.